Investment Thesis
Ginkgo Bioworks is a pre-commercial biotech company burning substantial cash with significant losses and negative margins across all profitability measures. While the company maintains adequate liquidity with $167.2M in cash and a 4.92x current ratio, the severe operating losses (-$315.3M), deteriorating revenue (-25.1% YoY), and substantial negative free cash flow (-$178.7M) indicate the business model has not yet achieved commercial viability. At the current cash burn rate, the company has limited runway without significant operational improvements or additional capital raises, presenting substantial execution risk.
Strengths
- Strong liquidity position with $167.2M cash and 4.92x current ratio provides runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Modest insider activity suggests some level of confidence from company leadership
Risks
- Severe operating losses of -$315.3M with -185.3% operating margin indicate business is far from profitability
- Revenue declined 25.1% year-over-year despite being pre-commercial, suggesting market execution challenges
- Negative free cash flow of -$178.7M annually will deplete cash reserves within approximately 12-15 months without improvement
- Diluted EPS of -$5.64 and negative ROE/ROA indicate value destruction for shareholders
- No gross profit reporting suggests potential product costing or revenue recognition issues
Key Metrics to Watch
- Revenue growth trajectory and return to positive growth rate
- Operating cash flow and free cash flow to assess path to cash flow breakeven
- Cash and equivalents levels and monthly burn rate relative to runway
- Gross margin when reportable to understand unit economics and product viability
- Operating expense reduction initiatives to achieve operating profitability timeline
Financial Metrics
Revenue
170.2M
Net Income
-312.8M
EPS (Diluted)
$-5.64
Free Cash Flow
-178.7M
Total Assets
1.1B
Cash
167.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-185.3%
Net Margin
-183.8%
ROE
-61.5%
ROA
-27.9%
FCF Margin
-105.0%
Balance Sheet & Liquidity
Current Ratio
4.92x
Quick Ratio
4.92x
Debt/Equity
0.00x
Debt/Assets
54.6%
Interest Coverage
-3,390.09x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T16:02:12.714311 |
Data as of: 2025-12-31 |
Powered by Claude AI